References
[1] Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11–66.
[2] Shaw J. Diagnosis of prediabetes. Med Clin North Am 2011;95:341–52.
[3] Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379:2279–90.
[4] Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–51.
[5] Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011;7:682–90.
[6] Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M. Prediabetes: to treat or not to treat? Eur J Pharmacol 2011;672:9–19.
[7] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
[8] Norris SL, Zhang X, Avenell A, Gregg E, Bwman B, Schmid CH, et al. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. Am J Prev Med 2005;28:126–39.
[9] Konig D, Deibert P, Frey I, Landmann U, Berg A. Effect of meal replacement on metabolic risk factors in overweight and obese subjects. Ann Nutr Metab 2008;52:74–8.
[10] Deibert P, König D, Schmidt-Trucksaess A, Zaenker KS, Frey I, Landmann U, et al. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. Int J Obes Relat Metab Disord 2004;28:1349–52.
[11] Noakes M, Foster PR, Keogh JB, Clifton PM. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. J Nutr 2004;134:1894–9.
[12] Berg A, Frey I, Landmann U, Deibert P, König D, Berg A, et al. Weight reduction by lifestyle intervention - 1-year results of a randomized controlled study in overweight or adipose subjects. Ernährungs Umschau 2005;52:310–4.
[13] Zaenker KS, Daftary GV, Gottschalk G, Adlercreutz H, Genistein. Mode of action and bioavailability as chemo-preventive agents in soy-enriched diet. Ger J Ophthalmol 2001;33:37–44.
[14] Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clin Chem 2011;57:215–20.
[15] Ho SC, Chen YM, Ho SS, Woo JL. Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial. Menopause 2007;14:905–12.
[16] Villegas R, Gao YT, Yang G, Li HL, Elasy TA, Zheng WM, et al. Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women’s Health Study. Am J Clin Nutr 2008;87:162–7.
[17] Mueller NT, Odegaard AO, Gross MD, Koh WP, Yu MC, Yuan JM, et al. Soy intake and risk of type 2 diabetes in Chinese Singaporeans. Eur J Nutr 2012;51:1033–40.
[18] Kwon DY, Daily JW III, Kim HJ, Park S. Antidiabetic effects of fermented soybean products on type 2 diabetes. Nutr Res 2010;30:1–13.
[19] Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003;133:1238–43.
[20] Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 2005;16:321–30.
[21] Morifuji M, Sanbongi C, Sugiura K. Dietary soya protein intake and exercise training have an additive effect on skeletal muscle fatty acid oxidation enzyme activities and mRNA levels in rats. Br J Nutr 2006;96:469–75.
[22] Sakane N, Sato J, Tsushita K, Tsujii S, Kotani K, Tsuzaki K, et al. Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011;11:40.
See all Almased Research